Dosing Study of Remifentanil for Smooth Removal of the Laryngeal Mask Airway (LMA)

Ajou University School of Medicine

Status and phase: Completed; Phase 4

Conditions: Drug Usage

Treatments: Device: laryngeal mask airway (LMA); Drug: remifentanil

Study type: Interventional

Funder types: Other

Identifiers

NCT01931683

AJIRB-MED-CT4-13

Details and patient eligibility

About

The investigators attempted to determine the optimal effect-site concentration of remifentanil for smooth removal of the LMA from propofol anesthesia.

Full description

At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to predetermined (initial concentration 1.0 ng/ml for the first patient). LMA removal was performed when the patients opened their eyes and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed.

Enrollment: 27 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ASA I-II patients undergoing general anesthesia for short elective surgery (<1 hr)

Exclusion criteria

• G-E reflux
• obesity (BMI>30)
• anticipated difficult airway

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: Double Blind

---

27 participants in 1 patient group

remifentanil

Experimental group

Description:

LMA removal was accomplished when remifentanil was maintained a predetermined concentration throughout the emergence periods.

Treatment:

Drug: remifentanil

Device: laryngeal mask airway (LMA)